Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein-Reference-Cited by-同舟云学术

Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein

Published:2017-08-05 Issue:9 Volume:15 Page:1829-1833
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Ay C.¹²^ORCID,Hisada Y.¹³,Cooley B. C.⁴,Mackman N.¹³

Affiliation:

1. Department of Medicine; Division of Hematology and Oncology, Thrombosis and Hemostasis Program; UNC McAllister Heart Institute; University of North Carolina at Chapel Hill; Chapel Hill NC USA

2. Clinical Division of Hematology and Hemostaseology; Department of Medicine I; Medical University of Vienna; Vienna Austria

3. K.G. Jebsen Thrombosis Research and Expertise Center; University of Tromsø; Tromsø Norway

4. Department of Pathology and Laboratory Medicine; McAllister Heart Institute; University of North Carolina at Chapel Hill; Chapel Hill NC USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13766/fullpdf

Reference21 articles.

1. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis;Mackman;Arterioscler Thromb Vasc Biol,2007

2. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?;Gailani;J Thromb Haemost,2007

3. Factor XI deficiency in humans;Seligsohn;J Thromb Haemost,2009

4. Factor XI deficiency;Gomez;Haemophilia,2008

5. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy;Salomon;Haemophilia,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B;Thrombosis Research;2024-06

2. Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis;Bleeding, Thrombosis and Vascular Biology;2024-05-16

3. Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies Factors II and XI as actionable anticoagulant targets;European Heart Journal Open;2024-05

4. Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics;Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine;2024-02-21

5. Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies Factors II and XI as actionable anticoagulant targets;2023-12-07